Insulin therapies remain essential for glycemic controlin diabetesmellitus, yet conventional subcutaneous injection is associated withpoor patient compliance, risk of hypoglycemia, and other adverse effects.Oral insulin formulations offer a promising alternative by improvingpatient adherence and mimicking the endogenous insulin pathway. The gene discussed is INS; the disease is Hypoglycemia.